Robert Paridaens
About
In The Last Decade
Robert Paridaens
297 papers receiving 9.6k citations
Hit Papers
Peers
Comparison fields: 5 of 142
- Oncology 6.3k
- Cancer Research 3.6k
- Genetics 3.3k
- Pulmonary and Respiratory Medicine 2.1k
- Molecular Biology 1.8k
Countries citing papers authored by Robert Paridaens
This map shows the geographic impact of Robert Paridaens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Paridaens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Paridaens more than expected).
Fields of papers citing papers by Robert Paridaens
This network shows the impact of papers produced by Robert Paridaens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Paridaens. The network helps show where Robert Paridaens may publish in the future.
Co-authorship network of co-authors of Robert Paridaens
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Paridaens. A scholar is included among the top collaborators of Robert Paridaens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Paridaens. Robert Paridaens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 8 | |
| 2 | 102 | |
| 3 | 40 | |
| 4 | Age Specific Competing Mortality In Breast Cancer Patients - a TEAM Study Analysis | 0 |
| 5 | Low 25-hydroxyvitamin d3 serum levels are associated with larger breast tumor size | 2 |
| 6 | 22 | |
| 7 | 58 | |
| 8 | 228 | |
| 9 | 93 | |
| 10 | 79 | |
| 11 | Extended adjuvant letrozole following five years of tamoxifen is cost-effective from a Belgian health care payer's perspective | 3 |
| 12 | Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) +/- trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data | 9 |
| 13 | Prospective study on the effect of endocrine treatments on menopausal symptoms in breast cancer patients | 1 |
| 14 | Clinical outcome of breast cancer patients with liver metastases in the anthracycline-taxane era | 1 |
| 15 | Impact of dose-intensity of adjuvant CMF on disease-free (DFS) and overall survival (OS) in breast cancer (BC): a retrospective analysis | 8 |
| 16 | Algorithms for the management of advanced breast cancer | 3 |
| 17 | Het effect van zelfzorginstructie op zelfzorgkennis en zelfzorggedrag bij vermoeidheid na radiotherapie en chemotherapie | 1 |
| 18 | Beoordeling van moeheid door verpleegkundigen | 1 |
| 19 | Psychosocial correlates of estrogen and progesterone receptors in breast cancer | 1 |
| 20 | Effect of prolactin and estradiol administration on the cell proliferation in the uterus and the MXT mouse mammary neoplasm | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.